Assessment of clinical efficacy of mesalazine suppositories on active mild or moderate ulcerative colonitis

Objective: To evaluate the efficacy and safety of Mesalazine Suppositories on the treatment of active mild or moderate ulcerative colitis(UC). Methods: 64 patients who were diagnosed as mild or moderate UC based on(the Consensus of cooperation of Chinese and western medicine diagnosis on treatment of ulcerative colitis in 2010) were enrolled in this randomized, multicenter, double blind, double dummy, andparallel controlled study. Among of them, 32 patients were assigned to receive 1.5 g mesalazine suppositories daily for 8 weeks(Group A), another 32 to orally receive 3 g Sulfasalazine tablets daily for 8 weeks(Group B). Results: The total effective rates of Group A and B were 90.625% and 71.875%, respectively. There was significant statistical difference between the two groups(P 0.05).The endoscopic index of Group A and B had significant statistical differences between before and 2,4, and 8 weeks after administration(P 0.05). The endoscopic index of Group A was much lower than that of Group B(P 0.05). The incidence of adverse reaction for group A and Group B was 3.125% and 31.25% during the treatment, with significant statistical difference between the two groups(P 0.05). Conclusion:Clinical curative effect of Mesalazine Suppositories on treating mild or moderate ulcerative colitis was more remarkable and safe.